Wall Street analysts start bullish on Omada Health on chronic care market growth Investing.com -- Barclays, Goldman Sachs, JP Morgan and Morgan Stanley issued bullish rating on Omada Health stock saying the virtual‑care provider could capture more of the large market for diabetes, hypertension and weight‑management services. Barclays began at “overweight” with a $21 price target, arguing Omada’s new GLP‑1 weight‑loss programme should speed adoption of its digital coaching platform. Goldman Sachs started at “buy” and set the Street‑high target of $29, saying a focus on measured clinical outcomes can help the company outgrow peers. JP Morgan initiated at “overweight” with a $19 target and projected roughly 24% compound annual revenue growth through 2027 as Omada expands its corporate client base. Morgan Stanley also rated the stock “overweight” and set a $25 target, citing scope for margin gains as artificial‑intelligence tools automate parts of the service. The brokerages see Omada tapping a U.S. population in which more than 150 million people live with at least one chronic condition. Several analysts said last year’s introduction of an integrated care track for users of GLP‑1 weight‑loss drugs, and recent partnerships with pharmacy‑benefit giants CVS Caremark and Express Scripts, should widen the company’s reach. San Francisco‑based Omada raised $158 million in its Nasdaq debut on June 6, pricing shares at $19. The stock has since traded below that level but is up roughly 20% from its low. Analysts said Omada’s move toward break‑even, targeted for the second half of 2026 or 2027 depending on the forecast, gives management flexibility to invest in new products while trimming debt. The company was valued at about $1.4 billion, or just under three times projected 2026 revenue, a discount to digital‑health peers, the broker notes said. With OMDA making headlines, savvy investors are asking: Is it truly valued fairly? In a market full of overpriced darlings, identifying true value can be challenging. InvestingPro's advanced AI algorithms have analyzed OMDA alongside thousands of other stocks to uncover hidden gems. These undervalued stocks, potentially including OMDA, could offer substantial returns as the market corrects. In 2024 alone, our AI identified several undervalued stocks that later surged by 30 or more. Is OMDA poised for similar growth? Don't miss the opportunity to find out.

Click Subscribe #OmadaHealth #ChronicCare #HealthcareInvestment #WallStreet #MarketGrowth

Digital health firm Omada prices $150m IPO In another sign of recovery in digital health investing, Omada Health has priced an IPO that could value the company at more than $1.1 billion

#Digitalhealth #OmadaHealth #initialpublicoffering #IPO #chronicconditions #diabetes #musculoskeletalconditions #MSKconditions #Nasdaq #HingeHealth #digitalhealthtechnology #DHT #postsurgicalrehabilitation #diabetesprevention #weightcontrol #reimbursementpathways
pharmaphorum.com/news/digital...

Omada Health debuts on Nasdaq with 40% rise from IPO price Investing.com -- Omada Health, a virtual healthcare provider, started trading on the Nasdaq Global Select Market today, with its shares opening at $23 each, which is above its initial public offering (IPO) price of $19 per share. Currently, the stock is trading at $26.50 per share, marking a nearly 40% increase from the IPO price. The company, which provides healthcare services between visits, announced yesterday that it had priced its IPO at $19 per share. The offering comprised of 7,900,000 shares of its common stock. Along with this, Omada Health granted underwriters a 30-day option to purchase up to an additional 1,185,000 shares of common stock at the initial offering price, minus underwriting discounts and commissions. The shares are listed on the Nasdaq Global Select Market under the ticker symbol "OMDA." As part of the offering, Morgan Stanley, Goldman Sachs & Co (NYSE:GS). LLC, and J.P. Morgan are serving as the lead book-running managers. This article was generated with the support of AI and reviewed by an editor. For more information see our T&C. Don't miss out on the next big opportunity! Stay ahead of the curve with ProPicks – 6 model portfolios fueled by AI stock picks with a stellar performance this year.. In 2024 alone, ProPicks' AI identified 2 stocks that surged over 150%, 4 additional stocks that leaped over 30%, and 3 more that climbed over 25%. That's an impressive track record. With portfolios tailored for Dow stocks, S&P stocks, Tech Stocks, and Mid Cap stocks, you can explore various wealth-building strategies. So if OMDA is on your watchlist, it could be very wise to know whether or not it made the ProPicks lists.

Click Subscribe #OmadaHealth #Nasdaq #IPO #StockMarket #Investing

Omada Health targets valuation of over $1 billion in US IPO (Reuters) -Virtual chronic care provider Omada Health is targeting a valuation of about $1.1 billion in its initial public offering in the United States, signaling a comeback for capital markets after several months of slowdown in listings. The company said on Thursday it would sell 7.9 million shares in a range of $18 to $20 per share, potentially fetching up to $158 million if priced at the upper limit. While U.S. President Donald Trump’s tariff whiplash has roiled markets and cast a shadow on new listings, companies in sectors perceived as less sensitive to economic headwinds are pushing ahead with their initial public offerings. The San Francisco, California-based company, last raised $192 million in a Series E funding round in 2022. J.P.Morgan, Goldman Sachs, Morgan Stanley and Barclays are among the underwriters for Omada’s offering.

Click Subscribe #OmadaHealth #IPO #Investment #StockMarket #Valuation

This is a privacy nightmare. You are not a product.

Fight back against silent health surveillance before it becomes the norm. If you’ve been enrolled in Omada without clear consent, you’re not alone.

We need to call this out.

#HealthDataScam #OmadaHealth #PrivacyRights #StopSurveillance

(5/5)